Judges at this year’s International Pharmaceutical Expo 2017 (INTERPHEX) have hailed Watson-Marlow Fluid Technology Group’s Quantum peristaltic pump as ‘cutting-edge’.
As winner of the Best Technological Innovation category, the Quantum peristaltic pump with patented ReNu SU Technology cartridge has been recognised as: ‘a technology with the potential to change the way pharmaceutical and biotech companies operate.’
Launched at INTERPHEX in March, Quantum offers a step change in pump technology for bioprocessing, enabling higher downstream process yields throughout the pressure range and exceeding the performance of any other pump available. Its patented single-use technology provides exceptional downstream process performance, delivering higher yields and improved flow linearity throughout the 3 bar pressure range. Quantum outperforms any other bioprocessing pump available, with ultra-low shear and a class leading 4000:1 turn down ratio
Commenting on the award win, Steve Lavargna, Sales and Marketing Director at Watson-Marlow Fluid Technology Group comments:
“When we designed Quantum, we wanted to redefine peristaltic pump performance for single-use downstream bioprocessing. We are very confident that this has been achieved. However, to have achieved external recognition from respected industry peers and experts is fantastic news on two levels. Firstly, it is well deserved by Quantum’s product development team – all of whom have worked so hard. Secondly, from a customer perspective, the award offers an additional layer of market confidence and advocacy in our leading-edge technology.”
Company name: Watson-Marlow Fluid Technology Group
Website: www.wmftg.com
E-mail: info@wmftg.co.uk
Diving Deep into Carrier-Based Formulation and Process Optimization
December 23rd 2024Carrier-based formulations for dry powder inhalers are carefully designed to transport extremely small particles into the lungs. Jet milling can be used to micronize these particles, with both high and low shear mixing processes used to formulate mixtures capable of carrying the fine API particles into the deep lung. This paper looks at the requirements for pulmonary delivery via carrier-based inhaled powder formulations, and how jet milling can be used to manufacture effective and stable materials for these formulations
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.